ESNATS
Embryonic Stem cell-based Novel Alternative Testing Strategies
| Coordinatore | KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 15˙592˙219 € |
| EC contributo | 11˙895˙577 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-04-01 - 2013-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | coordinator | 0.00 |
| 2 |
"THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON"
Organization address
address: Brunswick Square 29-39 contact info |
UK (LONDON) | participant | 0.00 |
| 3 |
ARTTIC
Organization address
address: Rue du Dessous des Berges 58A contact info |
FR (PARIS) | participant | 0.00 |
| 4 |
AVANTEA srl
Organization address
address: via Cabrini 12 contact info |
IT (Cremona) | participant | 0.00 |
| 5 |
BRUNEL UNIVERSITY
Organization address
address: Kingston Lane contact info |
UK (UXBRIDGE) | participant | 0.00 |
| 6 |
BUNDESINSTITUT FUER RISIKOBEWERTUNG
Organization address
address: MAX DOHRN STRASSE 8-10 contact info |
DE (BERLIN) | participant | 0.00 |
| 7 |
CELL CURE NEUROSCIENCES LTD
Organization address
address: KIRYAT HADASSAH MAIN BUILDING SIXTH contact info |
IL (JERUSALEM) | participant | 0.00 |
| 8 |
CONSORZIO PER L'INCREMENTO ZOOTECNICO SRL
Organization address
address: VIA MAREMMANA 17 A/C contact info |
IT (SAN MINIATO) | participant | 0.00 |
| 9 |
Department of Health
Organization address
address: Quarry House, Quarry Hill contact info |
UK (Leeds) | participant | 0.00 |
| 10 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
| 11 |
EDINETHICS LIMITED
Organization address
address: DUNDONALD STREET 11/6 contact info |
UK (EDINBURGH) | participant | 0.00 |
| 12 |
EUROPEAN CONSENSUS PLATFORM ON 3R-ALTERNATIVES TO ANIMAL EXPERIMENTATION
Organization address
address: Paul Deschanel Laan 36-38 contact info |
BE (BRUSSEL) | participant | 0.00 |
| 13 |
F. HOFFMANN-LA ROCHE AG
Organization address
address: GRENZACHERSTRASSE 124 contact info |
CH (BASEL) | participant | 0.00 |
| 14 |
FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E.V.
Organization address
address: ARDEYSTRASSE 67 contact info |
DE (DORTMUND) | participant | 0.00 |
| 15 |
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER
Organization address
address: Welfengarten 1 contact info |
DE (HANNOVER) | participant | 0.00 |
| 16 |
H. LUNDBECK A/S
Organization address
address: Ottiliavej 9 contact info |
DK (VALBY) | participant | 0.00 |
| 17 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 0.00 |
| 18 |
IN VITRO TESTING INDUSTRIAL PLATFORM
Organization address
address: AVENIDA DE LA INDUSTRIA 52 contact info |
ES (TRES CANTOS MADRID) | participant | 0.00 |
| 19 |
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Organization address
address: Rue de la Loi 200 contact info |
BE (BRUSSELS) | participant | 0.00 |
| 20 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 21 |
Medical Products Agency
Organization address
address: DAG HAMMARSKJOLDS VAG 42 contact info |
SE (UPPSALA) | participant | 0.00 |
| 22 |
N.V. ORGANON
Organization address
address: KLOOSTERSTRAAT 6 contact info |
NL (OSS) | participant | 0.00 |
| 23 |
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Organization address
address: Schoemakerstraat 97 contact info |
NL (DEN HAAG) | participant | 0.00 |
| 24 |
OU QURETEC
Organization address
address: ULIKOOLI 6A contact info |
EE (TARTU) | participant | 0.00 |
| 25 |
PROTEOSYS AG
Organization address
address: CARL ZEISSSTRASSE 51 contact info |
DE (MAINZ) | participant | 0.00 |
| 26 |
TAKARA BIO EUROPE AB
Organization address
address: ARVID WALLGRENS BACKE 20 contact info |
SE (GOETEBORG) | participant | 0.00 |
| 27 |
THE AUTOMATION PARTNERSHIP (CAMBRIDGE) LIMITED
Organization address
address: YORK WAY contact info |
UK (ROYSTON) | participant | 0.00 |
| 28 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 0.00 |
| 29 |
UNIVERSITAT KONSTANZ
Organization address
address: UNIVERSITATSSTRASSE 10 contact info |
DE (KONSTANZ) | participant | 0.00 |
| 30 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 0.00 |
| 31 |
UNIVERSITE DE LIEGE
Organization address
city: LIEGE contact info |
BE (LIEGE) | participant | 0.00 |
| 32 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 0.00 |
| 33 |
VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
BE (BRUSSEL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an 'all-in-one' test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems.'
Introduzione (Teaser)
A large European consortium developed a stem cell-based tool for accurate, fast and cost-effective identification of toxic compounds.